A N Cornforth

Summary

Affiliation: Hoag Cancer Center
Country: USA

Publications

  1. ncbi Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy
    Andrew N Cornforth
    Cell Biology Laboratory, Hoag Cancer Center, Newport Beach, CA 92663, USA
    J Clin Immunol 29:657-64. 2009
  2. ncbi Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival
    A N Cornforth
    Cell Biology Laboratory, Hoag Cancer Center, 1 Hoag Drive Bldg 41, 92663, Newport Beach, CA, USA
    Cancer Immunol Immunother 60:123-31. 2011
  3. ncbi Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial
    A N Cornforth
    Cell Biology Laboratory, Hoag Cancer Center, Newport Beach, CA 92663, USA
    J Biomed Biotechnol 2011:635850. 2011
  4. ncbi Characterization of interferon-?-treated melanoma tumor cells for use in dendritic cell-based immunotherapy
    Andrew N Cornforth
    Cell Biology Laboratory, Hoag Cancer Institute, Newport Beach, California 92663, USA
    Cancer Biother Radiopharm 26:345-51. 2011
  5. ncbi Establishment and characterization of a human primary prostate carcinoma cell line, HH870
    Senthamil R Selvan
    Patty and George Hoag Cancer Center, Newport Beach, California 92663, USA
    Prostate 63:91-103. 2005
  6. ncbi Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 24:311-9. 2009
  7. ncbi Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 25:553-7. 2010
  8. ncbi Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer
    R O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 15:161-8. 2000

Detail Information

Publications8

  1. ncbi Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy
    Andrew N Cornforth
    Cell Biology Laboratory, Hoag Cancer Center, Newport Beach, CA 92663, USA
    J Clin Immunol 29:657-64. 2009
    ..We examined cytokine, chemokine, and growth factor levels in serum collected from normal volunteers or metastatic melanoma patients receiving dendritic cell-based immunotherapy...
  2. ncbi Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival
    A N Cornforth
    Cell Biology Laboratory, Hoag Cancer Center, 1 Hoag Drive Bldg 41, 92663, Newport Beach, CA, USA
    Cancer Immunol Immunother 60:123-31. 2011
    ....
  3. ncbi Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial
    A N Cornforth
    Cell Biology Laboratory, Hoag Cancer Center, Newport Beach, CA 92663, USA
    J Biomed Biotechnol 2011:635850. 2011
    ..The sensitivity of ELISPOT in the context of patient-specific cellular vaccines is unclear...
  4. ncbi Characterization of interferon-?-treated melanoma tumor cells for use in dendritic cell-based immunotherapy
    Andrew N Cornforth
    Cell Biology Laboratory, Hoag Cancer Institute, Newport Beach, California 92663, USA
    Cancer Biother Radiopharm 26:345-51. 2011
    ..019). IFN-? treatment of melanoma cell lines prior to antigen loading of DCs may aid in antigen processing and presentation...
  5. ncbi Establishment and characterization of a human primary prostate carcinoma cell line, HH870
    Senthamil R Selvan
    Patty and George Hoag Cancer Center, Newport Beach, California 92663, USA
    Prostate 63:91-103. 2005
    ..Most in vitro studies have been carried out using a limited number of human prostate cancer cell lines that are mostly derived from metastatic tumors sites or are immortalized...
  6. ncbi Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 24:311-9. 2009
    ..016). This patient-specific vaccine warrants further investigation, based on its safety and encouraging survival rates. (Clinical Trial Number: NCI-V01-1646)...
  7. ncbi Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 25:553-7. 2010
    ..This is the first time she has been in a complete remission since her initial diagnosis. Patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases...
  8. ncbi Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer
    R O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Cancer Biother Radiopharm 15:161-8. 2000
    ..e., autologous vaccine) in such patients after resection of primary kidney cancer, and/or for the treatment of metastatic cancer...